Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that carries out the development of therapies for rare diseases in the field of cellular metabolism. The company's activities include the research, development, and commercialization of innovative medicines for hemolytic anemias. Its pipeline products include mitapivat, for thalassemia and sickle cell disease; AG-181 phenylalanine hydroxylase stabilizer that treats phenylketonuria (PKU); adult thalassemia, adult sickle cell disease, pediatric PK deficiency, pediatric thalassemia and pediatric sickle cell disease. The company operates in France, the US, Germany, Italy, Spain, the UK. Agios is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
88 Sidney Street, Cambridge, Massachusetts, 02139
Website
www.agios.com
Telephone
1 617 6498600
No of Employees
539
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AGIO (NASD)
Revenue (2024)
$54.0M
48%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-161.3%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
-141.4%
(2024 vs 2023)
* As of and is in US$
Agios Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | PYRUKYND |
| AG-181: | myAgios |
| Phenylketonuria | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received approval from the U.S. Food and Drug Administration for AQVESME (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of anemia in adults with alpha- or beta-thalassemia. |
| 2025 | Regulatory Approval | In August, the company received approval from the Saudi Food and Drug Authority for Pyrukynd (mitapivat) for adults with alpha or beta-thalassemia. |
| 2025 | Regulatory Approval | In January, the company received acceptance from the US Food and Drug Administration for PYRUKYND (mitapivat) to treat adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. |
Competitor Comparison
| Key Parameters | Agios Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | Bristol-Myers Squibb Co | Novo Nordisk AS |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Denmark |
| City | Cambridge | Rahway | New York City | Princeton | Bagsvaerd |
| State/Province | Massachusetts | New Jersey | New York | New Jersey | - |
| No. of Employees | 539 | 75,000 | 75,000 | 32,500 | 64,974 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jacqualyn A. Fouse, Ph.D. | Chairman | Executive Board | 2022 | 62 |
| Brian Goff | Chief Executive Officer; Director | Executive Board | 2022 | 56 |
| Cecilia Jones | Chief Financial Officer | Senior Management | 2022 | 50 |
| James Burns | Chief Legal Officer | Senior Management | 2022 | 47 |
| Ellen Lopresti | Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer